Contact Lens Spectrum
February 2001
Document #68
References
(p. 21) Potential Treatments for Dry Eye, Part I by Donald L. MacKeen, MS, PhD
1. Adler CA, Maurice DM, Paterson ME, The effect of viscosity of the vehicle on the
penetration of fluorescein into the human eye, Exp Eye Res (1971) 11(1):34-42
2. Akramanian J Wedrid A Nepp J amd Salor M " Estrogen therapy in
keratoconjunctivitis sicca Advan Exp Med Biol 438:1005-1009 (1998)
3. Avisar R Creter D, Levinsky, H Savir H " Comparative study o;f tear substitutes and
their immediate effect on the precorneal tear film" Isr J Med Sci 1997 33(3):1947-7
4. Basilice; Vincent P. Dispensing eye drops United States Patent 5,848,999 December
15, 1998
5. Beck RE , Bhagat HG, Gessel PD, Killinger FN Physiological tear compositions and
method for their preparation US Patent 5,403,598 April 4 1995
6. Bertera JH Stimulaton of lacrimal gland output : a tear jet for replacing eye moisture
in Sjogren's syndrome Adv, Med Biol 350:577-582 (1994
7. Bertera JH U S Patent 5,368,582 November 29, 1994 Method and apparatus for
introducing fluid material into an eye
8. Berry M. Pastis WK, Ellington RB, Frosts L Corfield AP and Easty DL "Hyaluronan
in dry eye and contact lens wearers" Adv Exp Med Biol 785-90 (1998)
9. Bodor NS Androstene derivatives US Patent 5,981,517 November 9, 1999 describes
new androstene derivatives with anti-inflammatory action
10. Bron AJ, Mangat H,qQuinlan M, Foley-Nolan A, Eustace P, Fsadni M, Sunder RP
Polyacrylic acid in patients with dry eyes: a randomized comparison with polyvinyl
alcohol Eur J Ophthalmol 1998 8(2):81-9
11. Canotoro A Ophthalmic preparation for use as artificial tears" U S Patent 5,770,628
June 23, 1998
12. Charlton JP Schwab IR Urea ophthalmic ointment and solution US Patent 5,629,344
May 13, 1997
13. Condon PI, McEwen CG, Wright M, MacKintosh G,Prescott RJ, McDonald C,
"Double blind, randomized placebo controlled, crossover, multicentre study to
determine the efficacy of a 0.1% (w/v) sodium hyaluronate solution (Fermavisc) in
the treatment of dry eye syndrome" B J Ophthalmol 1999 83(10):1121-4
14. Conti; F Methylated chitosans and their use for the preparation of pharmaceutical
compositions US Patent 4,826,826 May 2, 1989
15. Dartt DA, Donowitz M, Joshi VJ, Mathieu RS, Sharp GW Cyclic nucleotidedependent enzyme secretion in the rat lacrlimal gland J Physiol 352:375-84(1984)
16. Dikstein S Eye drops having non-Newtonian rheologicial properties US Patent
5,106,615 April 21, 1992
17. Ding S, Olejnlik O, Reis BL, " Emulsion eye drop for alleviation of dry eyes related
symptoms in dry eye patients and/or contact lens wearers" US Patent 5,981,607 Nov
9, 1999
18. Domb AJ Z Ocular inserts US Patent 5,660,851 August 26, 1997
19. Egerer I , Menzel J " Eye drops" US Patent 5,434,187 July 18, 1995
20. Edelhauser et al "Corneal epithelial tight junctions and the localization of surface
mucin"Adv Exp Med Biol 438:365-271(1998)
21. Foulks G " The now and future therapy of the non-Sjogrens dry eye" Advan Exp Med
Biol 438: 959-964 (1998)
22. Gilbard JP, Dartt DA "Stimulation of tear secretion with cyclic nucleotides" US
Patent 4,956,348 Sept 11, 1990
23. Gilbard JP Rossi,SR, Heydra KG, Dartt DA, Stimulation of tear secretionn and
treatment of dry-eye disease with 3-isobytyl-1-metshyl;xanthine, Arch Ophthalmol
1991, 109(5):672-6
24. Goebbels, MJ Spitznas M Influence of various pharmaceutical agents on tear flow as
assessed by fluorophotometry Adv Exp Med Biol 350: 385-891
25. Glonek; T ; Greiner; J V. ; Korb; D R US Patent 5,294,607* March 15, 1994
Dry eye treatment process and solution
26. Guo LSS Liposome composition for treating dry eye Oct 21, 1986 US Patent
4818537
27. Gokhale NS Cyanoacrylate lacrimal system occlusion after failed sac surgery" Indian
J Ophthalmol 1998 46(4):253-4
28. Grant WM Toxicology of the eye 2nd ed Grant WM C.C. Thomas Springfield IL
1974) p.1073]
29. Green, K, MacKeen, DL, Slagle T and Cheeks T,, " Tear Potassium contributes to
maintenance of corneal thickness" Ophthalmic Research 24: 99-102 1991
30. Greiner JV et al "Volume of the human and rabbit meibomian gland system" Adv Esp
Med Bio 1998 438:339-343`
31. Gressel PD Roehrs RE Ophthalmic carboxy vinyl polymer gel for dry eye syndrome
Dec 24, 1991 US Patent 5075104
32. Gunduz K and Ozdemir O "Topical cyclosporin therapy of keratoconjunctivitis sicca
in secondary Sjogrens" Acta Ophthalmol (Copenh). 1994 Aug;72(4):438-42
33. Herrick; RS.; Sardi; WF Intracanalicular implant for horizontal canalicular blockade
treatment of the eye U S Patent 5,053,030 October 1, 1991
34. Herrick RS, Method for treating an eye with a canalicular implant having a
collapsible flared section,United States Patent 5,163,959 November 17, 1992
35. Herrick RS "Canalicular implant having a collapsible flared section and method" US
Patent 5, 171,270 Dec 15, 1992
36. Hoeg AL, Meadows DL Reversible gelation emulsion compositions and methods of
use US Patent 5,441,732 August 15, 1995
37. Hamano T "Dry eye treatment with eye drops that stimulate mucin production
Advances Exp Med Biol 428: 965-968(1998)
38. Hamano; T; Miyata; T; Ogawara; T Method for obstructing lacrimal canaliculi with
infusable solution or dispersion United States Patent 5,840,054 . November 24, 1998
39. Hutnik CM et al " Argon laser punctal therapy versus thermal cautery for the
treatment of aqueous deficiency dry eye syndrome" Can J Ophthalmol 1998
33(7):365-72
40. Iga Yarisawa H, Ogane N, Saito Y, Tomizaka T, Nakagawa-Yagi, Y Masunaga H
Yasuda H Miyata N, (+/=) cis-2 methylspiro[1,3 oxathiolane-5,3'
quinuclidine
hydrochloride, hemihydrate (SNI2011, cevimeline hydrochloride) induces saliva and
tear secretions in rats and mice; the role of muscarinic acetylcholine receptors, Jpn J
Pharmacol 1998 78(3):373-80
41. Itoh S Ishii Y Mukai K and Kita K Ophthalmic composition containing active
Vitamin D US Patent 5,876,709 March 2, 1999
42. Joshi A, Ding S, Himmelstein KJ, Reversible gelation compositions and methods of
use" US Patent 5,252,318 October 12, 1993
43. Kabra BP Patent US Patent 5,827,835 October 27, 1998 Thermally-gelling emulsions
44. Kang M-C "Ophthalmic pharmaceutical composition" Us Patent 5,698,533 Dec 16,
1997
45. Kaufman; H E Artificial tear suspension US Patent 4923700
46. Korb DR, Greiner JV, Glonek T, Whalen A,HearnSL, Esway JE,Leahy CD, " Human
and rabbit lipid layer and intserference pattern observatrions"
47. Adv Exp med Biol 1998 , 438:305-308
48. Laibovits RA et al Cornea. 1993 Jul;12(4):315-23.
49. Lang,JC, Keister JC,Missel PJT, Stancioff, DJ Use of carageenins in topical
ophthalmic compositions US Patent 5,403,841, April 4, 1995
50. Lemp MA Artificial tear solutions International Ophthalmol Clinic, 1973.
13(1):226-229
51. Lemp MA Report of the National Eye Institute/Industry workshop on Clinical Trials
in Dry Eyes. CLAO J. 1995 Oct;21(4):221-32
52. Lemp MA, "New strategies in the treatment of dry-eye states" Cornea 1999,
18(6):625-632
53. Lopez Bernal D Ubels JL " Artificial tear composition and promotion of recovery of
tshe damaged corneal epithelium" Cornea 1993 12(2:115-20
54. Lubkin V US Patent 6,096,733 Aug 1, 2000 "Drugs for topical application of sex
steroids in the treatment of dry eye syndrome, and methods of preparation and
application"
55. MacKeen DL and Roth HW, A method and apparatus for modulating the flow of
lacrimal fluid through a punctum and associated canaliculus U.S. Patent 4,915,684,
April 10, 1990
56. MacKeen, DL US Patent 5,290,572 Ophthalmic composition for treating dry eye
(1994)
57. MacKeen, DL US Patent 5,366,739 Method of ophthalmic drug delivery (1994)
58. MacKeen DL Roth HW " Revolutionary method of ocular drug delivery IOVS 36(4):
S166 (1995)
59. MacKeen, DL US Patent 5,595,764 Ophthalmic Composition for treating dry eye
(1997)
60. MacKeen DL Roth HW and MacKeen PD, Supracutaneous treatment of dry eye
patients with calcium carbonate, in Lacrimal gland , tear film and dry eye syndromes
2 Sullivan Ed. Plenum Press NY 1998
61. MacKeen, DL and Roth, HW, A preliminary report on a new method for the
treatment of dry eye, Practical Optometry 6(3): 131-134 (1995)
62. MacKeen, DL, Roth, HW, Doane MA and MacKeen PD, "Supracutaneous treatment
of dry eye patients with calcium carbonate, Adv.Exp. Med 438: 887-889(1998)
Adv.Exp. Med 438:& Biol:985-990(1998)
63. MacKeen DL Composition for treating dry eye 5,830,508, November 3, 1998
64. MacKeen DL Ophthalmic composition for treating dry eye 5,290,572,March 12, 1994
65. MacKeen DL Method of ophthalmic drug delivery 5,366,739, November 22, 1994
66. MacKeen, DL, Roth, HW, Doane MA and MacKeen, AAF, "Investigations of a new
Ophthalmic drug delivery" Eye World, 3(4):64-66 April 1998
67. Mano T Sogo S "Lacrimation accelerating agent" US Patent 5,925,677 Jul 20, 1999
68. Martin NF Robinson HN Topical composition for treatment of blepharitis US Patent
5,614,545 March 25, 1997
69. Mathers WD Lane JA, Meibomian gland lipids evaporation and tear film stability
Adv Exp Med Biol 438:349-460 (1998)
70. Mauzuel C Pharmaceutical and or cosmetic composition for local use containing
Rhamsan gum US Patent 4996199 Feb 26, 1991
71. McCulley JP amd Shine WE, "Meibomian secretions in chronic blepharitis" Adv Exp
Med Biol 438:319-326
72. Mendius; R W. Punctum plug and method for inserting the same into the punctual
opening United States Patent 6,027,470 February 22, 2000
73. Mircheff "Hormonal support of lacrimal function, primary lacrimal deficiency ,
autoimmunity and peripheral tolerance in the lacrimal glands "Ocular Immunol
Inflam" 1996:145-172
74. Missel; P J. T. Lang; J C.; Jani; R, 5,696,166 Dec 9, 1997 U S Patent 5,212,162 ,Use
of combinations gelling polysaccharides and finely divided drug carrier substrates in
topical ophthalmic compositions
75. Murube J Murube A Zhuo C Classification of artificial tears Advances Adv Exp
Med Biol 438 705 (1998)
76. Nelson JD Drake MM Brewer JT Jr and Tuley M Evaluation of a phlkysioilogical
tear substature in patiens with keratoconjunctivitis sicca Adv Exp Med Biol 350:4537 (1994)
77. Nepp J Wedrich A Akramian J Derbolov A Mudrich C Ries E Schauersberger, J Dry
eye treatment with acupuncture Adv. Exp Med Biol 438:1011-1016 (1998)
78. Nepp J, Derbolov A, Haslinger-Akramian J, Mundrich C, Schauersberger J and
Wedlich , Akupunctureffekt bei Keratoconjunctivitis sicca" A: Klin Monatsbl
Augenheilkd. 1999 Oct;215(4):228-32]
79. Oechsneer M Keipert S " Polyacrylic acid/polyvinylpyrrolidone bipolymeric systems,
1. Rheological and mucoadhesive properties of formulations potentially useful for the
treatment of dry-eye-syndrome" Eur J Pharm Biopharm 1999 47(2):113-8
80. Ogawa T, Tokushige H Watanabe N Composition for treating cornea. US Patent
5,942,487 August 24, 1999
81. Paugh, JR, Chatelier PC, Huff, JW Research['Ocular residence time of
carboxymethylcellulose solutions"Adv. Exp Med Biol 438:761-768 (1998)
82. Pena N de la, Madoz SC " Patent on use of aloe vera ophthalmic solution for
treatment of the dry eye syndrome, inflammations, ulcerations, alkaline or acid burns,
infections and cataracts US Patent 6,013,259 Jan 11, 2000
83. Pflugfelder S "Advances in the diagnosis and management of keratoconjunctivitis
sicca., Curr Opin Ophthalmol. 1998 Aug;9(4):50-3
84. Pflugfelder SC Yoshino K Tseng SCG Huang AJW Use of secretory products of
human lacrimal gland acinar epithelia for tear replacement therapy US Patent
5,652,209 July 29, 1997
85. Pflugfelder SC, Tseng SCG, Huang AJW Non-preserved topical corticosteroid for
treatment of dry eye, filamentary keratitis, and delayed tear clearance (or turnover)
US Patent 6,153,607 November 28, 2000
86. Py, D Patent 4,908,024, March 13, 1990 Ocular self-treatment apparatus and method
87. (cited Kass MA, Hodnapp E, Gordon M Jikjer AE Goldberg I, Patient administration
of eyedrops: Observations, Part II Ann Ophthalmol 1982 14(9):889-93
88. Rumel S, Remulla H Rubin PA, Silicone punctal plug migration resulting in a
dacryocystitis and canaliculitis, Cornea 1997 16(3):377-9
89. Rios JD Zoukhri D Rawe IM Hodges RR Zieske JD Dart DA Immunolocalization of
muscarinic and VIP receptor subtypes and their role in stimulating goblet cell
secretion IOVS 40((6):1102-1111 (1999
90. Roth HW (1998) Use of corneal thickness changes to compare the efficacy of
conventional eye drops wlith supracutaneous treatment of dry eye Advances in Exp
Med and Biol 438: 887 (1998)
91. Saatei AO, Irkee M and Ozguknes H, " Zinc in tears" Ophthalmic Res (1991) 31-2
92. Sall K, Stevenson OD, Mundorf TK, Reis BL Two center, randomized stukdies of the
efficacy and safety of cyclosporine ophthalm emulsion in moderate to severe dry eye
disease CsA phase 3 study group Ophthalmology 107(4):631-9(2000)
93. Saetonne,MF, Burgalassi S, Giannaccini B, Boldini E, Bianchini P, Luciani G,
Ophthalmic solutions with tamarind seed polysaccharide US Patent 6,056,950 May
2000
94. Scheiner SA US Patent 5627611 May 6, 1997
Artificial tears
95. Schmitt P U S Patent 5469867 November 28, 1995 Cast-in place thermoplastic
channel occluder
96. Schoenwald Tertiary amines with cyclopropyl adjunct will decrease sting- have
antidepressant/antihypertensive actions 1998 Adv Exp Med Biol 438 p 96
97. Schoenwald RD Barfknecht CF " Ocular protein stimulants" US Patent 5,961,987 Oct
5, 1999
98. Seder; V.; Sardi; F. Lacrimal duct occluder United States Patent 4,959,048.
September 25, 1990
99. Shankar AH, Prasad AS, "Zinc and immune function: the biological basis of altered
resistance to infection" Am. J. Clin Nutr 1998 68(2 suppl):447S-463S
100. Smith, SG, US Patent 6,113,894 "Ophthalmic compositions and process of using"
101. Stern ME et al The pathology of dry eye: the interaction between the ocular
surface and lacrimal glands, Cornea 1998 17(6):584
102. Sullivan et al "Androgens regulation of the meibomian gland" Adv Exp Med Biol
1998, 438:327-331
103. Sullivan DA Krenzer KL Sullivan BD Tolls DB Toda I Dana MR " Does
androgen insufficiency cause lacrimal gland inflammation and aqueous tear
deficiency?" IVOS 1999 40(6):1261-5
104. Sullivan DA Ocular treatment in keratoconjunctivitis sicca using topically applied
androgen TGF beta US Patent 5,958,912 Sep 28,1999]
105. Sullivan DA Ocular treatment of keratoconjunctivitis sicca using topically applied
androgens of TGF-beta US Patent 5,958,912 [2000]
106. Sullivan DA, Wickham LA, Rocha EM Krenzer KL Sullivan DA, Steagall R
Cermak JM Dana MR Ullman MD Sato EH Gao J, Ono M Silveira LA Lamberts RW
Kelleher RS, Tolls DB, Soda I " Androgens and dry eye in Sjogren's syndrome" Ann
N Y Acad Sci 1999 876:312-24
107. Solomon A et al " The effect of a new tear substitute containing glycerol and
hyaluronate on keratoconjunctivitis sicca" J Ocul Pharmacol Ther 1998 14(6):497504
108. Sullivan D "Ocular therapy in keratoconjunctivitis sicca using topically applied
androgens of TGF-beta " U S patent 5,985,912 September 28, 1999
109. Tauber et al : Adv Exp Med Biol. 1998;438:969-72. "Topical cyclosporin
treatment of keratoconjunctivitis sicca in secondary Sjogren's syndrome".
110. Tsubota K Monden Y Yago Y GotoE Shimmura S "New treatment of dry eye: the
effect of calcium ointment through eyelid skin delivery" Br J Ophthalmol 1999,
83(7):767-70
111. Tsubota, K, Goto E, Shimmura S, Shimazaki J, Treatment of persistent corneal
epithelial defect by autologus serum appllication Ophthalmology 106(10) 1984-9
(1999)
112. Tsubota K "Tear dynamic and dry eye" Prog Retin Eye Res 17(4):565-96
113. Tsubota K, Goto E, Shimmura S, Shimazaki J " Treatment of persistent corneal
epithelial defect by autologous serum application" Ophthalmology 1999
106(10):1984-9
114. Tsybota K [2000]
115. Tsubota K Drug composition comprising albumin as the active ingredient US
Patent 6,043,213 Mar 28, 2000
116. Tsubota K Pharmaceutical composition comprising albumin as an active
ingredient US Patent 6,159,930 Dec 12, 2000
117. Tui VV Grounauer PA Portable device for programmable automatic, or ondemand delivery of artificial tears, Adv Exp Med Biol 438: 1027 (1998)
118. Vo; Van T. December 15, 1992 US Patent 5,171,306 Eyedrop delivery system
119. Watanabe H, Fabricant M, Tisdale AS, Spourr-M<ichaud, SJ, Lindberg K,
Gipson IK Human corneal and conjunctival epithelia produce a mucin-like
glycoprotein for the apical surface IOVS 19995, 36(2):337-41
120. Wilson CG et al " Ocular contact time of a carbomere gel (GelTears) in humans"
Br J Ophthalmol 1998 82(10):1131-4
121. Webb; N J Punctum plug United States Patent 6,016,806 Webb January 25, 2000
122. Wilson SE Liang Q Kim WJ Lacrimal gland HGF, KGF and EGF mRNA levels
increase after corneal epithelial wounding, IOVS 40(10)2185-2190 1999
123. Wilson SE, Li Q, Mohan RR,Tervo T,Vesaluoma M, Bennett GL, Schwall R,
124. Tabor K, Kim J, Hargrave S, Cuevas, KH " Lacrimal gland growth factors and
receptors:lacrimal fibrolbatic cells are a sourece of tear HGF, Ad Exp Med Biol
438:625-628 (1998)
125. Yanni JM, Gamache, DA, Miller ST " compositions containing
hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye
disorders" US Patent 5,696,166 Dec 9, 1997
126. Yerxa,BR Jacobus Km, Pendergast W, Rideout JL 1997 US Patent 5,900,407
Method of treating dry eye disease by stimulating fluid secretion with the topical
administration of uridine triphosphates and related compounds, May 4, `1999